



# Marksans Pharma Ltd.

Date: 23<sup>rd</sup> July, 2021

**BSE Limited**  
Corporate Relation Department  
Phiroze Jeejeeboi Towers,  
Dalal Street,  
Mumbai - 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai - 400051.  
Symbol: MARKSANS

Dear Sir,

Re: Outcome of Board Meeting

This is further to our intimation dated 14<sup>th</sup> July, 2021 and pursuant to the Special Resolution passed by the shareholders at the Extra-ordinary General Meeting held on 9<sup>th</sup> July, 2021, please be informed that the Board of Directors at its meeting held today, i.e., 23<sup>rd</sup> July, 2021, has created, issued and allotted convertible warrants on preferential basis as per details below:

- (c) 10,00,000 convertible warrants to Mr. Mark Saldanha (Promoter of the Company) at a price of INR 74.00 per warrant, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018; and
- (d) 4,93,24,324 convertible warrants to OrbiMed Asia IV Mauritius FVCI Limited at a price of INR 74.00 per warrant, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.

The details as required under SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 with respect to the preferential issue are given in **Annexure – A**.

The meeting of the Board of Directors commenced at 11:00 AM and concluded at 11:40 AM.


You are requested to note the above in your records.

Thanking You,

Enclosed as above



For Marksans Pharma Limited

  
Harshavardhan Panigrahi  
Company Secretary

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com  
www.marksanspharma.com

# Marksans Pharma Ltd.

## Annexure - A Details regarding Preferential Allotment

Sr. No.	Particulars	Details
1	Type of securities issued (viz. Equity shares, convertibles etc.)	Convertible Warrants with right exercisable by the warrant holder to subscribe to one equity share of Re. 1/- face value per warrant.
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.
3	Total number of securities issued or the total amount for which the securities issued (approximately)	(c) 10,00,000 convertible warrants each carrying a right exercisable by the warrant holder to subscribe to one equity share of face value of Re 1/- each per warrant. (d) 4,93,24,324 convertible warrants each carrying a right exercisable by the warrant holder to subscribe to one equity share of face value of Re 1/- each per warrant.
	<b>Additional details in case of preferential issue</b>	
4	Name of investors	(c) Mr. Mark Saldanha (Promoter) (10,00,000 warrants) (d) OrbiMed Asia IV Mauritius FVCI Limited (4,93,24,324 warrants)
5	Number of Investors	2
6	Post allotment of securities- outcome of the subscription:	(a) Issue price of each Warrant: Rs 74. (25% of the issue price of each Warrant paid upfront for allotment of the Warrants. The remaining 75% of the issue price of each Warrant shall be payable at the time of conversion of the said Warrants into equity shares of the Company.) (b) Conversion ratio of each Warrant: 1:1. (c) Each Warrant can be converted into one equity share of the Company at any time within eighteen months from the date of allotment of Warrants.
7	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Will be intimated at the time of conversion

## Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com  
www.marksanspharma.com

